| Vol. 23.38 – 7 November, 2022 |
| |
|
|
| Researchers analyzed the salvage treatments and outcomes of 79 patients with multiple myeloma from two academic institutions who had progression of disease after treatment with B cell maturation antigen-directed CAR T. [Blood] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators developped tissue-engineered nerve grafts to simultaneously “bridge” missing nerve segments and “babysit” regenerative capacity by providing living axons to guide host axons and maintain the distal pathway. [Science Advances] |
|
|
|
| To investigate the impact of granulocyte colony-stimulating factor, the authors analyzed 197 patients treated with anti-CD19 CAR T for lymphoma and 47 patients treated with anti-B cell maturation antigen CAR T for multiple myeloma. [Blood Cancer Journal] |
|
|
|
| Investigators designed a multicenter, retrospective study with the main objective of comparing progression-free survival and overall survival of patients with peripheral T-cell lymphomas who underwent autologous stem cell transplantation in complete remission after first-line chemotherapy. [Haematologica] |
|
|
|
| Scientists co-transplanted 250 islets and 20,000 adipose tissue-derived microvascular fragments (MVF) from donor mice under the kidney capsule as well as 500 or 1000 islets with 40,000 MVF into the subcutaneous space of diabetic mice. [NPJ Regenerative Medicine] |
|
|
|
| Researchers tested whether repairing the gut via intestinal epithelial stem cell transplants would also improve stroke recovery. [Brain, Behavior, and Immunity] |
|
|
|
| In vivo studies in lymphoma-bearing immunodeficient mice demonstrated enhanced antitumor efficacy of human CD19 CAR-T. In contrast to mice treated with CAR-T alone, those that received CAR-T and NKTR-255 had markedly higher CAR-T counts in blood and marrow. [Blood Advances] |
|
|
|
| Scientists evaluated the clinical impact of CD3+ cell count in peripheral blood at leukapheresis on clinical outcomes of CAR-T cell therapy. [Scientific Reports] |
|
|
|
| Human adipose-derived mesenchymal stem cells were administrated in the articular cavity by injection in vivo and co-cultured with chondrocytes using transwell in vitro. [Inflammation Research] |
|
|
|
|
| The authors highlight recent progress in induced pluripotent stem cells (iPSCs) editing and guided differentiation to develop natural killer (NK) and T cell products for immunotherapy. [Blood] |
|
|
|
| Scientists demonstrate an association between hypophosphatemia and CAR T cell-induced immune effector cell–associated neurotoxicity syndrome. [Cancer Immunology Research] |
|
|
|
|
| The US FDA has set out proposals for the New Alternative Methods Program that will focus on replacing, reducing and refining the use of laboratory animals through the adoption of cutting-edge alternative methods. [Nature News] |
|
|
|
| Aleta Biotherapeutics announced that the UK Medicines and Healthcare products Regulatory Agency has granted an Innovation Passport under the Innovative Licensing and Access Pathway for CAR T cell therapy Engager candidate ALETA-001 for the treatment of patients suffering from the B-cell malignancies. [Aleta BioTherapeutics] |
|
|
|
|
| January 23 – 25, 2023 Breckenridge, Colorado, United States |
|
|
|
|
|
| University Medical Center of the Johannes Gutenberg University Mainz – Mainz, Germany |
|
|
|
| University of Nebraska Medical Center – Omaha, Nebraska, United States |
|
|
|
| Aspect Biosystems – Vancouver, British Columbia, Canada |
|
|
|
| University of Texas Health Science Center at Houston – Houston, Texas, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|